<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        17-475-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROLIA 60MG/ML SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DENOSUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        974.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AMGEN EUROPE B.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AMGEN EUROPE B.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AMGEN EUROPE B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Prolia is and how it works</strong></p><p>&nbsp;</p><p>Prolia contains denosumab, a protein (monoclonal antibody) that interferes with the action of another protein, in order to treat bone loss and osteoporosis. Treatment with Prolia makes bone stronger and less likely to break.</p><p><strong>&nbsp;</strong></p><p>Bone is a living tissue and is renewed all the time. Oestrogen helps keep bones healthy. After the menopause, oestrogen level drops which may cause bones to become thin and fragile. This can eventually lead to a condition called osteoporosis. Osteoporosis can also occur in men due to a number of causes including ageing and/or a low level of the male hormone, testosterone. It can also occur in patients receiving glucocorticoids. Many patients with osteoporosis have no symptoms, but they are still at risk of breaking bones, especially in the spine, hips and wrists.</p><p>&nbsp;</p><p>Surgery or medicines that stop the production of oestrogen or testosterone used to treat patients with breast or prostate cancer can also lead to bone loss. The bones become weaker and break more easily.</p><p>&nbsp;</p><p><strong>What Prolia is used for</strong></p><p>&nbsp;</p><p>Prolia is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteoporosis in women after the menopause (postmenopausal) and men who have an increased risk of fracture (broken bones), reducing the risk of spinal, non-spinal and hip fractures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone loss that results from a reduction in hormone (testosterone) level caused by surgery or treatment with medicines in patients with prostate cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone loss that results from long-term treatment with glucocorticoids in patients who have an increased risk of fracture.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Prolia is and how it works</strong></p><p>&nbsp;</p><p>Prolia contains denosumab, a protein (monoclonal antibody) that interferes with the action of another protein, in order to treat bone loss and osteoporosis. Treatment with Prolia makes bone stronger and less likely to break.</p><p><strong>&nbsp;</strong></p><p>Bone is a living tissue and is renewed all the time. Oestrogen helps keep bones healthy. After the menopause, oestrogen level drops which may cause bones to become thin and fragile. This can eventually lead to a condition called osteoporosis. Osteoporosis can also occur in men due to a number of causes including ageing and/or a low level of the male hormone, testosterone. It can also occur in patients receiving glucocorticoids. Many patients with osteoporosis have no symptoms, but they are still at risk of breaking bones, especially in the spine, hips and wrists.</p><p>&nbsp;</p><p>Surgery or medicines that stop the production of oestrogen or testosterone used to treat patients with breast or prostate cancer can also lead to bone loss. The bones become weaker and break more easily.</p><p>&nbsp;</p><p><strong>What Prolia is used for</strong></p><p>&nbsp;</p><p>Prolia is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteoporosis in women after the menopause (postmenopausal) and men who have an increased risk of fracture (broken bones), reducing the risk of spinal, non-spinal and hip fractures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone loss that results from a reduction in hormone (testosterone) level caused by surgery or treatment with medicines in patients with prostate cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone loss that results from long-term treatment with glucocorticoids in patients who have an increased risk of fracture.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>The recommended dose is one pre-filled syringe of 60&nbsp;mg administered once every 6 months, as a single injection under the skin (subcutaneous). The best places to inject are the top of your thighs and the abdomen. Your carer can also use the outer area of your upper arm. Please consult your doctor on the date for a potential next injection. Each pack of Prolia contains a reminder card, that can be removed from the carton and used to keep a record of the next injection date.</p><p>&nbsp;</p><p>You should also take calcium and vitamin D supplements while being on treatment with Prolia. Your doctor will discuss this with you.</p><p>&nbsp;</p><p>Your doctor may decide that it is best for you or a carer to inject Prolia. Your doctor or healthcare provider will show you or your carer how to use Prolia. For instructions on how to inject Prolia, please read the section at the end of this leaflet.</p><p>&nbsp;</p><p><strong>If you forget to use Prolia</strong></p><p>&nbsp;</p><p>If a dose of Prolia is missed, the injection should be administered as soon as possible. Thereafter, injections should be scheduled every 6&nbsp;months from the date of the last injection.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop using Prolia</strong></p><p>&nbsp;</p><p>To get the most benefit from your treatment in reducing the risk of fractures, it is important to use Prolia for as long as your doctor prescribes it for you. Do not stop your treatment without contacting your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Uncommonly, patients receiving Prolia may develop skin infections (predominantly cellulitis). <strong>Please tell your doctor immediately</strong> if you develop any of these symptoms while being on treatment with Prolia: swollen, red area of skin, most commonly in the lower leg, that feels hot and tender, and possibly with symptoms of fever.</p><p><strong>&nbsp;</strong></p><p>Rarely, patients receiving Prolia may develop pain in the mouth and/or jaw, swelling or non-healing of sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). <strong>Tell your doctor and dentist immediately</strong> if you experience such symptoms while being treated with Prolia or after stopping treatment.</p><p><strong>&nbsp;</strong></p><p>Rarely, patients receiving Prolia may have low calcium levels in the blood (hypocalcaemia). Symptoms include spasms, twitches, or cramps in your muscles, and/or numbness or tingling in your fingers, toes or around your mouth and/or seizures, confusion, or loss of consciousness. If any of these apply to you, <strong>tell your doctor immediately</strong>. Low calcium in the blood may also lead to a change in heart rhythm called QT prolongation which is seen by electrocardiogram (ECG).</p><p>&nbsp;</p><p>Rarely unusual fractures of the thigh bone may occur in patients receiving Prolia. <strong>Contact your doctor</strong> if you experience new or unusual pain in your hip, groin or thigh as this may be an early indication of a possible fracture of the thigh bone.</p><p>&nbsp;</p><p>Rarely, allergic reactions may occur in patients receiving Prolia. Symptoms include swelling of the face, lips, tongue, throat or other parts of the body; rash, itching or hives on the skin, wheezing or difficulty breathing. <strong>Please tell your doctor</strong> if you develop any of these symptoms while being treated with Prolia.</p><p><strong>&nbsp;</strong></p><p><strong>Very common side effects</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone, joint, and/or muscle pain which is sometimes severe,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arm or leg pain (pain in extremity).</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10&nbsp;people):</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful urination, frequent urination, blood in the urine, inability to hold your urine,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, tingling or numbness that moves down your leg (sciatica),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal discomfort,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin condition with itching, redness and/or dryness (eczema),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss (alopecia).</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, vomiting and abdominal pain or discomfort (diverticulitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear infection,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash that may occur on the skin or sores in the mouth (lichenoid drug eruptions).</p><p><strong>&nbsp;</strong></p><p><strong>Very rare side effects</strong> (may affect up to 1 in 10,000 people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction that can damage blood vessels mainly in the skin (e.g. purple or brownish-red spots, hives or skin sores) (hypersensitivity vasculitis).</p><p><strong>&nbsp;</strong></p><p><strong>Not known </strong>(frequency cannot be estimated from the available data):</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you have ear pain, discharge from the ear and/or an ear infection. These could be signs of bone damage in the ear.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Keep the container in the outer carton in order to protect from light.</p><p>Do not shake.</p><p>&nbsp;</p><p>Your pre-filled syringe may be left outside the refrigerator to reach room temperature (up to 25&deg;C) before injection. This will make the injection more comfortable. Once your syringe has been left to reach room temperature (up to 25&deg;C), it must be used within 30&nbsp;days.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>&nbsp;</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is denosumab. Each 1&nbsp;mL pre-filled syringe contains 60&nbsp;mg of denosumab (60&nbsp;mg/mL).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients in each 1 mL are: acetic acid glacial (1 mg), sodium hydroxide (approximately 0.3 mg per dose), sorbitol E420 (47 mg), polysorbate&nbsp;20 (0.1 mg) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Prolia is a clear, colourless to slightly yellow solution for injection provided in a ready to use pre-filled syringe.

Each pack contains one pre-filled syringe with a needle guard.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amgen Europe B.V.</p><p>Minervum 7061,</p><p>4817 ZK Breda,</p><p>The Netherlands</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	

		This leaflet was last revised in May 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو بروليا وكيف يعمل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي بروليا على دينوسوماب وهو بروتين (جسم مضاد أحادي النسيلة) يعطل عمل بروتين آخر من أجل معالجة فقدان العظام وهشاشة العظام. إن العلاج باستخدام بروليا يجعل العظام أقوى وأقل عرضة للكسر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">فالعظم نسيج حي يتجدد باستمرار. ويساهم الاستروجين في الحفاظ على صحة العظام، حيث أنه بعد انقطاع الطمث تنخفض معدلات الاستروجين مما يجعل العظام أرق وأضعف. وقد يؤدي ذلك إلى الإصابة بمرض يعرف باسم هشاشة العظام. من الممكن للرجال أيضا أن يصابوا بهشاشة العظام نتيجة لعدد من الأسباب منها التقدم في السن و/أو انخفاض مستويات التستوستيرون وهو هرمون الذكورة. يمكن أن يصيب أيضاً المرضى الذين يتلقون الهرمونات القشرية السكرية. وكثير من المصابين بمرض هشاشة العظام لا يشعرون بأية أعراض إلا أنهم على الرغم من ذلك عرضة لخطر كسر العظام خاصة على مستوى العمود الفقري، الوركين والرسغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن العمليات الجراحية أو الأدوية المستخدمة في علاج المرضى المصابين بسرطان الثدي أو البروستات لوقف إنتاج الاستروجين أو التستوستيرون من شأنها أيضا التسبب في فقدان العظام. فتصبح العظام أضعف ويسهل كسرها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيما يستخدم بروليا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم بروليا في علاج كل من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هشاشة العظام بعد انقطاع الطمث لدى السيدات و لدى الرجال الذين لديهم خطورة متزايدة للإصابة بالكسور (تكسر العظام)، حيث إنه يقلل من خطورة الإصابة بالكسور الشوكية، اللاشوكية والوركية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان العظام الناتج عن انخفاض معدلات الهرمونات (التستوستيرون) بسبب العمليات الجراحية أو العلاج بالأدوية لدى الرجال المصابين بسرطان البروستات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان العظام الناتج عن علاج طويل الأمد باستخدام الهرمونات القشرية السكرية لدى المرضى الذين لديهم خطورة متزايدة للإصابة بالكسور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بروليا في الحالات التالية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك انخفاض في مستوى الكالسیوم في الدم (انخفاض مستوى الكالسیوم في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية من دينوسوماب أو غيره من مكونات ھذا الدواء (الواردة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذیرات والاحتیاطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي قبل استخدام بروليا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء تلقيك العلاج باستخدام بروليا، قد تصاب بعدوى جلدية تسبب ظهور أعراض مثل منطقة وذمية، أو احمرار بالجلد، وبشكل عام ما يتم ملاحظته في الجزء السفلي من الساق من حرارة موضوعية ولين (الالتهاب الخلوي)، وما قد يصاحب ذلك من أعراض منها ارتفاع في درجة حرارة الجسم. يرجى إخطار الطبيب المعالج في الحال إذا ما لاحظت أيا من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك أيضا أن تتناول مكملات الكالسيوم وفيتامين د أثناء علاجك باستخدام بروليا. سيناقشك طبيبك في هذا الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون مستويات الكالسيوم في دمك منخفضة أثناء تلقيك العلاج باستخدام بروليا. الرجاء إخبار طبيبك فورا إذا لاحظت أيا من الأعراض التالية: تشنجات أو نفضات أو تقلصات (مَعَص) بعضلاتك و/أو أحسست بخدر أو وخز في أصابع يديك أو قدميك أو حول فمك و/أو إذا تعرضت لنوبات أو ارتباك أو فقدت وعيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إخطار الطبيب المعالج إذا كان لديك أو إذا كان قد حدث لك من قبل مشاكل كلوية حادة، أو قصور كلوي أو احتجت غسيل كلى أو كنت تتناول أدوية تُعرف بالهرمونات القشرية السكرية (مثل بريدنيزولون أو ديكساميثازون)، والتي قد تزيد من خطر الاصابة بانخفاض مستوى الكالسيوم في الدم في حالة عدم تناول مكملات الكالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مشكلات في الفم أو الأسنان أو الفك</u></p><p dir="RTL">نادرا ما تم الإبلاغ عن أثر جانبي يُدعى تنخر عظم الفك (ONJ) (تلف عظمي في الفك) (والذي قد يصيب شخصا واحدا عن كل ١٠٠٠ شخص) لدى المرضى الذين يتعاطون البروليا لعلاج هشاشة العظام. ويزداد خطر الإصابة بتنخر عظم الفك (ONJ) لدى المرضى الذين يخضعون للعلاج لفترة طويلة (بما قد يؤثر على شخص واحد من بين ٢٠٠ شخص في حالة استمرار العلاج لعشر&nbsp; سنوات). ويمكن أيضا أن يحدث تنخر عظم الفك (ONJ) بعد إيقاف العلاج. من المهم أن تحاول منع تطور تنخر عظم الفك (ONJ) وذلك لأنه قد يكون مؤلما للغاية ومن الصعب معالجته. ولتقليل خطورة حدوث تنخرعظم الفك &rlm;(&rlm;ONJ&rlm;)&rlm;، يجب أخذ الاحتياطات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل تلقي العلاج، أخبر طبيبك أو ممرضتك (أخصائي الرعاية الصحية) في حالة:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في فمك أو أسنانك مثل ضعف الأسنان، مرض اللثة، أو خلع أسنان مخطط له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تتلق الرعاية المعتادة للأسنان أو لم تجر فحص أسنان منذ فترة طويلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مدخنا (حيث إن ذلك يتسبب في زيادة خطورة المشاكل بالأسنان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت مسبقا للمعالجة ببيسفوسوفونات (يستخدم لعلاج أو منع حدوث اضطرابات العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتعاطى أدوية تسمّى الستيرويدات القشرية (مثل بريدنيزولون أو ديكساميثازون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يطلب منك طبيبك الخضوع لفحص أسنان قبل أن تبدأ العلاج ببروليا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء تلقيك للعلاج يجب أن تحافظ على رعاية صحية جيدة للفم وأن تقوم بفحوصات منتظمة لأسنانك. إذا كنت ممن يركبون أسنانا صناعية، تأكد من أنها مثبتة على نحو صحيح. إذا كنت تخضع لمعالجة أسنان أو سوف تقوم بجراحة أسنان (مثلا خلع أسنان)، أخبر طبيبك عن معالجة الأسنان التي تقوم بها وأخبر طبيب الأسنان الخاص بك أنك تُعالج باستخدام بروليا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك وطبيب الأسنان الخاص بك على الفور إذا واجهت أي مشاكل في فمك أو أسنانك مثل أسنان مخلخلة، ألم أو تورم، عدم التئام للتقرحات أو إفرازات، لأن كل هذه الأعراض تمثل علامات تنخر عظم الفك (ONJ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>كسور غير مألوفة في عظم الفخذ</u></p><p dir="RTL">لقد أُصيب بعض المرضى بكسور غير مألوفة في عظام الفخذ أثناء الخضوع للعلاج باستخدام بروليا. اتصل بالطبيب إذا ما شعرت بحالة جديدة أو غير معتادة من الألم في منطقة الورك أو الأربية أو الفخذ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراھقون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي استخدام بروليا لدى الأطفال والمراھقين دون الثامنة عشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى و بروليا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت في الآونة الأخيرة أو من المحتمل أن تتناول أدوية أخرى. ومن الضروري إخبار طبيبك إذا كنت تعالج بأي دواء يحتوي على دينوسوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ولا ينبغي تناول بروليا مع أي دواء آخر يحتوي على دينوسوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يتم اختبار بروليا لدى الحوامل. ومن الضروري إخبار طبيبك إذا كنت حاملا، أو تعتقدين أنك حاملا، أو تخططين للحمل، ولا يوصى باستخدام بروليا إذا كنت حاملا. ينبغي على النساء القادرات على الإنجاب استخدام وسائل فعالة لمنع الحمل أثناء معالجتهن ببروليا ولمدة ٥&nbsp;شهور على الأقل بعد وقف العلاج ببروليا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحت حاملاً أثناء العلاج ببروليا أو بعد أقل من ٥&nbsp;شهور من وقف العلاج ببروليا، يُرجى إخبار طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف إذا كان بروليا يتم إفرازه في حليب الرضاعة الطبيعية، ومن المهم إخبار طبيبك إذا كنت ترضعين رضاعة طبيعية أو تخططين لذلك. وسيساعدك الطبيب بدوره في اتخاذ قرار وقف الرضاعة الطبيعية أو وقف العلاج باستخدام بروليا، نظرا لأهمية الرضاعة الطبيعية للمولود وحسب فوائد العلاج باستخدام بروليا للأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت ترضعين رضاعة طبيعية أثناء العلاج ببروليا، يرجى الاتصال بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عليك استشارة طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يؤثر تناول بروليا أو له تأثير ضئيل على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بروليا على السوربيتول</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على ٤٧&nbsp;مجم سوربيتول في كل مل من المحلول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بروليا على الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١&nbsp;ملمول صوديوم (٢۳&nbsp;مجم) لكل ٦٠&nbsp;مجم، بمعنى أنه أساسا &quot;خال من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة الموصى بها هي حقنة مملوءة مسبقا ٦٠&nbsp;مجم يتم تناولها عن طريق الحقن تحت الجلد في جرعة واحدة، مرة كل ٦&nbsp;أشهر. والمناطق التي يوصى بحقنها هي أعلى الفخذ والبطن. مقدم الرعاية الخاص بك يمكنه أن يحقنك في الجزء العلوي من الذراع. يرجى استشارة طبيبك حول تاريخ الحقنة التالية المحتملة. تحتوي كل عبوة من بروليا على بطاقة تذكير يمكن إزالتها من العلبة واستخدامها للاحتفاظ بسجل لموعد الحقنة التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وينبغي عليك أيضا أن تتناول مكملات الكالسيوم والفيتامين د أثناء العلاج باستخدام بروليا. سيناقشك طبيبك في هذا الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وسوف يقرر طبيبك المعالج حسب حالتك ما إذا كان الأفضل أن تحقن نفسك ببروليا أم يقوم مقدم الرعاية بحقنك. وسوف يقوم طبيبك أو متخصص الرعاية الصحية بتوضيح كيفية استخدام بروليا لك أو لمقدم الرعاية الخاص بك. أما بالنسبة للتعليمات الخاصة بطريقة حقن بروليا، فيمكنك قراءة الفقرة الموضحة آخر هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا ما نسيت استخدام بروليا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ما نسيت إحدى جرعات بروليا، يجب أخذ الحقنة في أسرع وقت ممكن. وبالتالي، يجب وضع جدول للحقن كل ٦&nbsp;أشهر اعتبارا من موعد آخر حقنة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا ما توقفت عن استخدام بروليا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أفضل نتيجة من العلاج في تقليل خطورة حدوث الكسور، من المهم استخدام بروليا طوال المدة الموضحة في وصفة الطبيب. لا توقف علاجك من دون الاتصال بطبيبك.</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء كغيره من الأدوية آثارا جانبية، إلا أنها قد لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرا ما يتعرض المرضى الذين يتناولون بروليا لعدوى الجلد (غالبا الالتهاب الخلوي).<strong> يرجى الاتصال بالطبيب في الحال </strong>إذا ما شعرت بأي من هذه الآثار أثناء العلاج ببروليا: منطقة من الجلد متورمة ومصابة بالاحمرار، مع حرارة موضوعية ولين، ويمكن ملاحظتها بشكل عام على الجزء الأسفل من الساق، وقد يصاحبها ارتفاع في درجة الحرارة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">وفي حالات نادرة، قد يعاني المرضى الذين يتعاطون بروليا من ألم بالفم و/أو الفك، تورم أو تقرحات غير ملتئمة بالفم أو الفك، إفرازات، خدر أو إحساس بثقل في الفك، أو تخلخل للأسنان. وقد تكون كل هذه الأعراض علامات لتلف عظام الفك (تنخر العظم).<strong> أخبر طبيبك وطبيب أسنانك على الفور</strong> إذا تعرضت لمثل تلك الأعراض أثناء تلقيك العلاج باستخدام بروليا أو بعد توقفك عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفي حالات نادرة، قد يعاني المرضى الذين يتعاطون بروليا من انخفاض مستوى الكالسيوم في الدم (نقص كالسيوم الدم). وتتضمن الأعراض تشنجات، ارتجافات، أو تشنجات عضلية، و/أو خدرا أو وخزا بأصابع يديك، أصابع قدميك أو حول فمك و/أو نوبات، ارتباك، أو فقدان الوعي. إذا حدث أي من الأعراض السابقة لديك، <strong>أخبر طبيبك على الفور</strong>. وقد يؤدي نقص الكالسيوم في الدم أيضا إلى تغير في ضربات القلب يُسمَّى استطالة الـ QT والتي تظهر بواسطة التخطيط الكهربائي البياني للقلب (ECG).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث إصابات كسور نادرة وغير معتادة في عظم الفخذ وذلك لدى المرضى الخاضعين للعلاج ببروليا.<strong> اتصل بطبيبك</strong> إذا شعرت بحالة جديدة أو غير معتادة للألم في الورك أو الأربية أو الفخذ لأن ذلك قد يمثل مؤشرا مبكرا على احتمال الإصابة بكسر في عظم الفخذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفي حالات نادرة، قد تحدث تفاعلات تحسسية لدى المرضى الذين يتلقون بروليا. وتشتمل الأعراض على تورم الوجه أو الشفتين أو اللسان أو الحلق أو غيره من الأجزاء الأخرى للجسم، كما تظهر أعراض الطفح الجلدي أو الحكة أو الشرى على الجلد، أو الأزيز أو صعوبة في التنفس.<strong> يرجى الاتصال بطبيبك </strong>إذا ظهرت عليك أي من هذه الأعراض أثناء الخضوع للعلاج باستخدام بروليا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدا</strong> (قد تصيب أكثر من ١ عن كل ١٠ أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم قد يكون شديدا في بعض الأحيان، في العظام و/أو المفاصل و/أو العضلات،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراع أو الساق (ألم بالأطراف).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong>(قد تصيب ١ عن كل ١٠ أشخاص):</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عند التبول، تبول متكرر، دم في البول، سلس البول،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو وخز أو خدر يتحرك إلى أسفل الساق (عرق النسا)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بانزعاج بالبطن،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (طفح)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض جلدي مع حكة واحمرار و/أو جفاف (إكزيما)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر(داء الثعلبة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong>(قد تصيب ١ عن كل ١٠٠ شخص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في درجات الحرارة وقئ وألم أو اضطراب في البطن (إلتهاب الرتج)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالأذن؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي قد يصيب الجلد أو تقرحات بالفم (طفحات دوائية حزازية الشكل).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا</strong> (قد تصيب ١ عن كل ١٠٠٠٠&nbsp;شخص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي يمكن أن يؤدي إلى تلف الأوعية الدموية في الجلد خاصة (مثل ظهور نقاط أرجوانية أو حمراء ضاربة للون البني أو شَرَى أو تقرحات على الجلد) (التهاب وعائي مفرط الحساسية).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير المعروفة </strong>(لا يمكن تحديد معدل ظهورها من واقع البيانات المتاحة):</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك إذا أُصبت بألم في الأذن، أو في حالة خروج إفرازات من الأذن و/أو الإصابة بعدوى في الأذن. فقد تشير هذه الأعراض إلى حدوث تلف في عظام الأذن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأي آثار جانبية، يرجى إبلاغ طبيبك أو الصيدلي. ويشمل ذلك أي آثار جانبية غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بالدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العلبة والملصق بعد كلمة EXP، حيث يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في الثلاجة (٢&deg;م&nbsp;-&nbsp;٨&deg;م).</p><p dir="RTL">لا يجمد.</p><p dir="RTL">احتفظ بالحاوية في العلبة الخارجية لحماية الدواء من الضوء.</p><p dir="RTL">لا ترج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إخراج الحقنة المملوءة مسبقا من الثلاجة لتمكينها من الوصول إلى درجة حرارة الغرفة (بحيث لا تتعدى ٢٥&deg;م) قبل الحقن، مما يجعل عملية الحقن أكثر راحة. عندما تصل الحقنة إلى درجة حرارة الغرفة (بحيث لا تتعدى ٢٥&deg;م)، يمكن استخدامها في غضون ٣٠ يوما بحد أقصى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تلق بالأدوية بمياه الصرف أو الفضلات المنزلية، وعليك باستشارة الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها، فمثل تلك الإجراءات تساعد على حماية البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عما يحتوي بروليا</strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي الدينوسوماب، وكل حقنة ١&nbsp;مل مملوءة مسبقا تحتوي على ٦٠&nbsp;مجم من الدينوسوماب (٦٠&nbsp;مجم/ مل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى في كل ١&nbsp;مل هي: حامض الاستيك الجلاسيال (١&nbsp;مجم)، هيدروكسيد الصوديوم (حوالي ٠٫٣&nbsp;مجم لكل جرعة)، سوربيتول ٤٢٠&rlm;&lrm;E &rlm;(٤٧&nbsp;مجم)، بولي سوربيت&nbsp;٢٠ (٠٫١&nbsp;مجم)، وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل بروليا ومحتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">بروليا هو عبارة عن محلول صاف قابل للحقن، وهو بلا لون وقد يميل إلى الاصفرار ويقدم في حقنة مملوءة مسبقا جاهزة للاستعمال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وكل عبوة &nbsp;تحتوي على حقنة مملوءة مسبقا مع جهاز آمن للإبرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Amgen Europe B.V.</p><p dir="RTL">Minervum 7061</p><p dir="RTL">4817 ZK Breda,</p><p dir="RTL">هولندا</p><p dir="RTL">للحصول على أي معلومات حول هذا الدواء، يرجى الاتصال بالمندوب المحلي لصاحب ترخيص التسويق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تاريخ آخر مراجعة لهذه النشرة: مايو ٢٠٢٢.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolia 60 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe contains 60 mg of denosumab in 1 mL of solution (60 mg/mL).

Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese hamster ovary cells) by recombinant DNA technology.

Excipient with known effect
This medicine contains 47 mg sorbitol in each mL of solution. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear, colourless to slightly yellow solution. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non-vertebral and hip fractures.</p><p>&nbsp;</p><p>Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.</p><p>&nbsp;</p><p>Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology </u></p><p><u>&nbsp;</u></p><p>The recommended dose of Prolia is 60&nbsp;mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or upper arm.</p><p>&nbsp;</p><p>Patients must be adequately supplemented with calcium and vitamin D (see section 4.4).</p><p>&nbsp;</p><p>Patients treated with Prolia should be given the package leaflet and the patient reminder card.</p><p>&nbsp;</p><p>The optimal total duration of antiresorptive treatment for osteoporosis (including both denosumab and bisphosphonates) has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of denosumab on an individual patient basis, particularly after 5 or more years of use (see section 4.4).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with renal impairment (see section 4.4 for recommendations relating to monitoring of calcium).</p><p><u>&nbsp;</u></p><p>No data is available in patients with long-term systemic glucocorticoid therapy and severe renal impairment (GFR &lt; 30&nbsp;mL/min).</p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p>The safety and efficacy of denosumab have not been studied in patients with hepatic impairment (see section 5.2).</p><p><strong><em>&nbsp;</em></strong></p><p><em>Elderly (age &ge;&nbsp;65)</em></p><p>No dose adjustment is required in elderly patients.</p><p><strong>&nbsp;</strong></p><p><em>Paediatric population </em></p><p>Prolia should not be used in children aged &lt;&nbsp;18 years because of safety concerns of serious hypercalcaemia, and potential<em> </em>inhibition of bone growth and lack of tooth eruption (see sections 4.4 and 5.3).</p><p><strong><em>&nbsp;</em></strong></p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>For subcutaneous use.</p><p><u>&nbsp;</u></p><p>Administration should be performed by an individual who has been adequately trained in injection techniques.</p><p>&nbsp;</p><p>The instructions for use, handling and disposal are given in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Hypocalcaemia (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability</p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><strong>&nbsp;</strong></p><p><u>Calcium and vitamin D supplementation</u></p><p><u>&nbsp;</u></p><p>Adequate intake of calcium and vitamin D is important in all patients.</p><p>&nbsp;</p><p><u>Precautions for use</u></p><p>&nbsp;</p><p><em>Hypocalcaemia</em></p><p>It is important to identify patients at risk for hypocalcaemia. Hypocalcaemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy. Clinical monitoring of calcium levels is recommended before each dose and, in patients predisposed to hypocalcaemia within two weeks after the initial dose. If any patient presents with suspected symptoms of hypocalcaemia during treatment (see section 4.8 for symptoms) calcium levels should be measured. Patients should be encouraged to report symptoms indicative of hypocalcaemia.</p><p>&nbsp;</p><p>In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported (see section 4.8), with most cases occurring in the first weeks of initiating therapy, but it can occur later.</p><p><em>&nbsp;</em></p><p>Concomitant glucocorticoid treatment is an additional risk factor for hypocalcaemia.</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>Patients with severe renal impairment (creatinine clearance &lt;&nbsp;30&nbsp;mL/min) or receiving dialysis are at greater risk of developing hypocalcaemia. The risks of developing hypocalcaemia and accompanying parathyroid hormone elevations increase with increasing degree of renal impairment. Adequate intake of calcium, vitamin D and regular monitoring of calcium is especially important in these patients, see above.</p><p><em>&nbsp;</em></p><p><em>Skin infections</em></p><p>Patients receiving Prolia may develop skin infections (predominantly cellulitis) leading to hospitalisation (see section 4.8). Patients should be advised to seek prompt medical attention if they develop signs or symptoms of cellulitis.</p><p><em>&nbsp;</em></p><p><em>Osteonecrosis of the jaw (ONJ)</em></p><p>ONJ has been reported rarely in patients receiving Prolia for osteoporosis (see section 4.8).</p><p>&nbsp;</p><p>The start of treatment/new treatment course should be delayed in patients with unhealed open soft tissue lesions in the mouth. A dental examination with preventive dentistry and an individual benefit‑risk assessment is recommended prior to treatment with denosumab in patients with concomitant risk factors.</p><p>&nbsp;</p><p>The following risk factors should be considered when evaluating a patient&rsquo;s risk of developing ONJ:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potency of the medicinal product that inhibits bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to head and neck.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease, invasive dental procedures (e.g. tooth extractions).</p><p>&nbsp;</p><p>All patients should be encouraged to maintain good oral hygiene, receive routine dental check‑ups, and immediately report any oral symptoms such as dental mobility, pain or swelling or non-healing of sores or discharge during treatment with denosumab. While on‑treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to Prolia administration.</p><p>&nbsp;</p><p>The management plan of the patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.</p><p><em>&nbsp;</em></p><p><em>Osteonecrosis of the external auditory canal</em></p><p>Osteonecrosis of the external auditory canal has been reported with denosumab. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving denosumab who present with ear symptoms including chronic ear infections.</p><p>&nbsp;</p><p><em>Atypical fractures of the femur</em></p><p>Atypical femoral fractures have been reported in patients receiving denosumab (see section 4.8). Atypical femoral fractures may occur with little or no trauma in the subtrochanteric and diaphyseal regions of the femur. Specific radiographic findings characterise these events. Atypical femoral fractures have also been reported in patients with certain co-morbid conditions (e.g. vitamin D deficiency, rheumatoid arthritis, hypophosphatasia) and with use of certain pharmaceutical agents (e.g. bisphosphonates, glucocorticoids, proton pump inhibitors). These events have also occurred without antiresorptive therapy. Similar fractures reported in association with bisphosphonates are often bilateral; therefore the contralateral femur should be examined in denosumab-treated patients who have sustained a femoral shaft fracture. Discontinuation of Prolia therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient based on an individual benefit/risk assessment. During denosumab treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated for an incomplete femoral fracture.</p><p>&nbsp;</p><p><em>Long-term antiresorptive treatment </em></p><p>Long-term antiresorptive treatment (including both denosumab and bisphosphonates) may contribute to an increased risk for adverse outcomes such as osteonecrosis of the jaw and atypical femur fractures due to significant suppression of bone remodelling (see section 4.2).</p><p>&nbsp;</p><p><em>Concomitant treatment with other denosumab-containing medicinal products</em></p><p>Patients being treated with Prolia should not be treated concomitantly with other denosumab‑containing medicinal products (for prevention of skeletal related events in adults with bone metastases from solid tumours).</p><p>&nbsp;</p><p><em>Hypercalcaemia in paediatric patients</em></p><p>Prolia should not be used in paediatric patients (age &lt;&nbsp;18). Serious hypercalcaemia has been reported. Some clinical trial cases were complicated by acute renal injury.</p><p>&nbsp;</p><p><em>Warnings for excipients</em></p><p>This medicine contains 47&nbsp;mg sorbitol in each mL of solution. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 60&nbsp;mg that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In an interaction study, Prolia did not affect the pharmacokinetics of midazolam, which is metabolised by cytochrome P450 3A4 (CYP3A4). This indicates that Prolia should not alter the pharmacokinetics of medicinal products metabolised by CYP3A4.</p><p>&nbsp;</p><p>There are no clinical data on the co-administration of denosumab and hormone replacement therapy (oestrogen), however the potential for a pharmacodynamic interaction is considered to be low.</p><p>&nbsp;</p><p>In postmenopausal women with osteoporosis the pharmacokinetics and pharmacodynamics of denosumab were not altered by previous alendronate therapy, based on data from a transition study (alendronate to denosumab).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p><u>&nbsp;</u></p><p>There are no or limited amount of data from the use of denosumab in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Prolia is not recommended for use in pregnant women and women of child-bearing potential not using contraception. Women should be advised not to become pregnant during and for at least 5&nbsp;months after treatment with Prolia. Any effects of Prolia are likely to be greater during the second and third trimesters of pregnancy since monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether denosumab is excreted in human milk. In genetically engineered mice in which RANKL has been turned off by gene removal (a &ldquo;knockout mouse&rdquo;), studies suggest absence of RANKL (the target of denosumab see section 5.1) during pregnancy may interfere with maturation of the mammary gland leading to impaired lactation post-partum (see section 5.3). A decision on whether to abstain from breast-feeding or to abstain from therapy with Prolia should be made, taking into account the benefit of breast-feeding to the newborn/infant and the benefit of Prolia therapy to the woman.</p><p>&nbsp;</p><p><u>Fertility </u></p><p><u>&nbsp;</u></p><p>No data are available on the effect of denosumab on human fertility. Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolia has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most common side effects with Prolia (seen in more than one patient in ten) are musculoskeletal pain and pain in the extremity. Uncommon cases of cellulitis, rare cases of hypocalcaemia, hypersensitivity, osteonecrosis of the jaw and atypical femoral fractures (see section 4.4 and section 4.8 - description of selected adverse reactions) have been observed in patients taking Prolia.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>The data in table 1 below describe adverse reactions reported from phase II and III clinical trials in patients with osteoporosis and breast or prostate cancer patients receiving hormone ablation; and/or spontaneous reporting.</p><p><strong><em>&nbsp;</em></strong></p><p>The following convention has been used for the classification of the adverse reactions (see table 1): very common (&ge;&nbsp;1/10), common (&ge; 1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare&nbsp;(&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000),&nbsp; very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1. Adverse reactions reported in </strong><strong>patients with osteoporosis and breast or prostate cancer patients receiving hormone ablation</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA </strong><strong>system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p><p>Common</p><p>Uncommon</p><p>Uncommon</p><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary tract infection</p><p>Upper respiratory tract infection</p><p>Diverticulitis<sup>1</sup></p><p>Cellulitis<sup>1</sup></p><p>Ear infection</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p><p>Rare</p></td><td style="vertical-align:top"><p>Drug hypersensitivity<sup>1</sup></p><p>Anaphylactic reaction<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypocalcaemia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sciatica</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p><p>Common</p></td><td style="vertical-align:top"><p>Constipation</p><p>Abdominal discomfort</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p><p>Common</p><p>Common</p><p>Uncommon</p><p>Very rare</p></td><td style="vertical-align:top"><p>Rash</p><p>Eczema</p><p>Alopecia</p><p>Lichenoid drug eruptions<sup>1</sup></p><p>Hypersensitivity vasculitis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p><p>Very common</p><p>Rare</p><p>Rare</p><p>Not known</p></td><td style="vertical-align:top"><p>Pain in extremity</p><p>Musculoskeletal pain<sup>1</sup></p><p>Osteonecrosis of the jaw<sup>1</sup></p><p>Atypical femoral fractures<sup>1</sup></p><p>Osteonecrosis of the external auditory canal<sup>2</sup></p></td></tr></tbody></table><p><sup>1</sup> See section Description of selected adverse reactions.</p><p><sup>2 </sup>See section 4.4.</p><p>&nbsp;</p><p>In a pooled analysis of data from all phase II and phase III placebo-controlled studies, influenza-like illness was reported with a crude incidence rate of 1.2% for denosumab and 0.7% for placebo. Although this imbalance was identified via a pooled analysis, it was not identified via a stratified analysis.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Hypocalcaemia</em></p><p>In two phase III placebo-controlled clinical trials in postmenopausal women with osteoporosis, approximately 0.05% (2 out of 4,050) of patients had declines of serum calcium levels (less than 1.88&nbsp;mmol/L) following Prolia administration. Declines of serum calcium levels (less than 1.88&nbsp;mmol/L) were not reported in either the two phase III placebo-controlled clinical trials in patients receiving hormone ablation or the phase III placebo-controlled clinical trial in men with osteoporosis.</p><p>&nbsp;</p><p>In the post-marketing setting,&nbsp;rare cases of severe symptomatic hypocalcaemia have been reported predominantly&nbsp;in patients at increased risk of hypocalcaemia receiving Prolia, with most cases occurring in the first weeks of initiating therapy. Examples of the clinical manifestations of severe symptomatic hypocalcaemia have included QT interval prolongation, tetany, seizures and altered mental status (see section 4.4). Symptoms of hypocalcaemia in denosumab clinical studies included paraesthesias or muscle stiffness, twitching, spasms and muscle cramps.</p><p><em>&nbsp;</em></p><p><em>Skin infections</em></p><p>In phase III placebo-controlled clinical trials, the overall incidence of skin infections was similar in the placebo and the Prolia groups: in postmenopausal women with osteoporosis (placebo [1.2%, 50 out of 4,041] versus Prolia [1.5%, 59 out of 4,050]); in men with osteoporosis (placebo [0.8%, 1 out of 120] versus Prolia [0%, 0 out of 120]); in breast or prostate cancer patients receiving hormone ablation (placebo [1.7%, 14 out of 845] versus Prolia [1.4%, 12&nbsp;out of 860]). Skin infections leading to hospitalisation were reported in 0.1% (3 out of 4,041) of postmenopausal women with osteoporosis receiving placebo versus 0.4% (16&nbsp;out of 4,050) of women receiving Prolia. These cases were predominantly cellulitis. Skin infections reported as serious adverse reactions were similar in the placebo (0.6%, 5 out of 845) and the Prolia (0.6%, 5 out of 860) groups in the breast and prostate cancer studies.</p><p>&nbsp;</p><p><em>Osteonecrosis of the jaw</em></p><p>ONJ has been reported rarely, in 16 patients, in clinical trials in osteoporosis and in breast or prostate cancer patients receiving hormone ablation including a total of 23,148 patients (see section 4.4). Thirteen of these ONJ cases occurred in postmenopausal women with osteoporosis during the phase&nbsp;III clinical trial extension following treatment with Prolia for up to 10 years. Incidence of ONJ was 0.04% at 3 years, 0.06% at 5 years and 0.44% at 10 years of Prolia treatment. The risk of ONJ increased with duration of exposure to Prolia.</p><p><em>&nbsp;</em></p><p><em>Atypical fractures of the femur</em></p><p>In the osteoporosis clinical trial programme, atypical femoral fractures were reported rarely in patients treated with Prolia (see section 4.4).</p><p>&nbsp;</p><p><em>Diverticulitis </em></p><p>In a single phase III placebo-controlled clinical trial in patients with prostate cancer receiving androgen deprivation therapy (ADT), an imbalance in diverticulitis adverse events was observed (1.2% denosumab, 0% placebo). The incidence of diverticulitis was comparable between treatment groups in postmenopausal women or men with osteoporosis and in women undergoing aromatase inhibitor therapy for non-metastatic breast cancer.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Drug-related hypersensitivity reactions </em></p><p>In the post-marketing setting, rare events of drug-related hypersensitivity, including rash, urticaria, facial swelling, erythema, and anaphylactic reactions have been reported in patients receiving Prolia.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Musculoskeletal pain</em></p><p>Musculoskeletal pain, including severe cases, has been reported in patients receiving Prolia in the post-marketing setting. In clinical trials, musculoskeletal pain was very common in both denosumab and placebo groups. Musculoskeletal pain leading to discontinuation of study treatment was uncommon.</p><p><em>&nbsp;</em></p><p><em>Lichenoid drug eruptions</em></p><p>Lichenoid drug eruptions (e.g. lichen planus-like reactions), have been reported in patients in the post‑marketing setting.</p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><u>Other special populations</u></p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Prolia should not be used in paediatric patients (age &lt;&nbsp;18). Serious hypercalcaemia has been reported. Some clinical trial cases were complicated by acute renal injury.</p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>In clinical studies, patients with severe renal impairment (creatinine clearance &lt;&nbsp;30&nbsp;mL/min) or receiving dialysis were at greater risk of developing hypocalcaemia in the absence of calcium supplementation. Adequate intake of calcium and vitamin D is important in patients with severe renal impairment or receiving dialysis (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:552px"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:</p><p>Saudi Arabia:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdose in clinical studies. Denosumab has been administered in clinical studies using doses up to 180&nbsp;mg every 4 weeks (cumulative doses up to 1,080&nbsp;mg over 6&nbsp;months), and no additional adverse reactions were observed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for the treatment of bone diseases &ndash; Other drugs affecting bone structure and mineralisation, ATC code: M05BX04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Prolia treatment rapidly reduced the rate of bone turnover, reaching a nadir for the bone resorption marker serum type 1 C-telopeptides (CTX) (85% reduction) by 3 days, with reductions maintained over the dosing interval. At the end of each dosing interval, CTX reductions were partially attenuated from maximal reduction of &ge;&nbsp;87% to approximately &ge;&nbsp;45% (range 45-80%), reflecting the reversibility of Prolia&rsquo;s effects on bone remodelling once serum levels diminish. These effects were sustained with continued treatment. Bone turnover markers generally reached pre-treatment levels within 9 months after the last dose. Upon re-initiation, reductions in CTX by denosumab were similar to those observed in patients initiating primary denosumab treatment.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>In clinical studies, neutralising antibodies have not been observed for denosumab. Using a sensitive immunoassay &lt;&nbsp;1% of patients treated with denosumab for up to 5 years tested positive for non neutralising binding antibodies with no evidence of altered pharmacokinetics, toxicity, or clinical response.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in postmenopausal women</u><u> </u><u>with osteoporosis</u></p><p><u>&nbsp;</u></p><p>Efficacy and safety of Prolia administered once every 6 months for 3 years were investigated in postmenopausal women (7,808 women aged 60-91 years, of which 23.6% had prevalent vertebral fractures) with baseline bone mineral density (BMD) T-scores at the lumbar spine or total hip between &ndash;2.5 and &ndash;4.0 and a mean absolute 10-year fracture probability of 18.60% (deciles: 7.9‑32.4%) for major osteoporotic fracture and 7.22% (deciles: 1.4-14.9%) for hip fracture. Women with other diseases or on therapies that may affect bone were excluded from this study. Women received calcium (at least 1,000&nbsp;mg) and vitamin D (at least 400&nbsp;IU) supplementation daily.</p><p>&nbsp;</p><p><em>Effect on vertebral fractures</em></p><p>Prolia significantly reduced the risk of new vertebral fractures at 1, 2 and 3&nbsp;years (p&nbsp;&lt;&nbsp;0.0001) (see table 2).</p><p>&nbsp;</p><p><strong>Table 2. The effect of Prolia on the risk of new vertebral fractures</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Proportion of women with fracture (%)</p></td><td rowspan="2" style="vertical-align:top"><p>Absolute risk reduction (%)</p><p>(95% CI)</p></td><td rowspan="2" style="vertical-align:top"><p>Relative risk reduction (%)</p><p>(95% CI)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>n = 3,906</p></td><td style="vertical-align:top"><p>Prolia</p><p>n = 3,902</p></td></tr><tr><td style="vertical-align:top"><p>0-1 year</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>1.4 (0.8, 1.9)</p></td><td style="vertical-align:top"><p>61 (42, 74)**</p></td></tr><tr><td style="vertical-align:top"><p>0-2 years</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>3.5 (2.7, 4.3)</p></td><td style="vertical-align:top"><p>71 (61,79)**</p></td></tr><tr><td style="vertical-align:top"><p>0-3 years</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>4.8 (3.9, 5.8)</p></td><td style="vertical-align:top"><p>68 (59, 74)*</p></td></tr></tbody></table><p>*p&nbsp;&lt;&nbsp;0.0001, **p&nbsp;&lt;&nbsp;0.0001 &ndash; exploratory analysis</p><p>&nbsp;</p><p><em>Effect on hip fractures</em></p><p>Prolia demonstrated a 40% relative reduction (0.5% absolute risk reduction) in the risk of hip fracture over 3 years (p&nbsp;&lt;&nbsp;0.05). The incidence of hip fracture was 1.2% in the placebo group compared to 0.7% in the Prolia group at 3 years.</p><p>&nbsp;</p><p>In a post-hoc analysis in women &gt;&nbsp;75&nbsp;years, a 62% relative risk reduction was observed with Prolia (1.4% absolute risk reduction, p&nbsp;&lt;&nbsp;0.01).</p><p>&nbsp;</p><p><em>Effect on all clinical fractures</em></p><p>Prolia significantly reduced fractures across all fracture types/groups (see table 3).</p><p>&nbsp;</p><p><strong>Table 3. The effect of Prolia on the risk of clinical fractures over 3 years</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Proportion of women with fracture (%)<sup>+</sup></p></td><td rowspan="2" style="vertical-align:top"><p>Absolute risk reduction (%)</p><p>(95% CI)</p></td><td rowspan="2" style="vertical-align:top"><p>Relative risk reduction (%)</p><p>(95% CI)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>n = 3,906</p></td><td style="vertical-align:top"><p>Prolia</p><p>n = 3,902</p></td></tr><tr><td style="vertical-align:top"><p>Any clinical fracture<sup>1</sup></p></td><td style="vertical-align:top"><p>10.2</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>2.9 (1.6, 4.2)</p></td><td style="vertical-align:top"><p>30 (19, 41)***</p></td></tr><tr><td style="vertical-align:top"><p>Clinical vertebral fracture</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.8 (1.2, 2.4)</p></td><td style="vertical-align:top"><p>69 (53, 80)***</p></td></tr><tr><td style="vertical-align:top"><p>Non-vertebral fracture<sup>2</sup></p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>1.5 (0.3, 2.7)</p></td><td style="vertical-align:top"><p>20 (5, 33)**</p></td></tr><tr><td style="vertical-align:top"><p>Major non-vertebral fracture<sup>3</sup></p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>1.2 (0.1, 2.2)</p></td><td style="vertical-align:top"><p>20 (3, 34)*</p></td></tr><tr><td style="vertical-align:top"><p>Major osteoporotic fracture<sup>4</sup></p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>2.7 (1.6, 3.9)</p></td><td style="vertical-align:top"><p>35 (22, 45)***</p></td></tr></tbody></table><p>*p &le; 0.05, **p = 0.0106 <em>(secondary endpoint included in multiplicity adjustment),</em> ***p&nbsp;&le; 0.0001</p><p><sup>+</sup> Event rates based on Kaplan-Meier estimates at 3 years.</p><p><sup>1</sup> Includes clinical vertebral fractures and non-vertebral fractures.</p><p><sup>2</sup> Excludes those of the vertebrae, skull, facial, mandible, metacarpus, and finger and toe phalanges.</p><p><sup>3</sup> Includes pelvis, distal femur, proximal tibia, ribs, proximal humerus, forearm, and hip.</p><p><sup>4</sup> Includes clinical vertebral, hip, forearm, and humerus fractures, as defined by the WHO.</p><p>&nbsp;</p><p>In women with baseline femoral neck BMD &le;&nbsp;‑2.5, Prolia reduced the risk of non-vertebral fracture (35% relative risk reduction, 4.1% absolute risk reduction, p&nbsp;&lt;&nbsp;0.001, exploratory analysis).</p><p>&nbsp;</p><p>The reduction in the incidence of new vertebral fractures, hip fractures and non-vertebral fractures by Prolia over 3 years were consistent regardless of the 10-year baseline fracture risk.</p><p>&nbsp;</p><p><em>Effect on bone mineral density</em></p><p>Prolia significantly increased BMD at all clinical sites measured, versus placebo at 1, 2 and 3 years. Prolia increased BMD by 9.2% at the lumbar spine, 6.0% at the total hip, 4.8% at the femoral neck, 7.9% at the hip trochanter, 3.5% at the distal 1/3 radius and 4.1% at the total body over 3 years (all p&nbsp;&lt;&nbsp;0.0001).</p><p>&nbsp;</p><p>In clinical studies examining the effects of discontinuation of Prolia, BMD returned to approximately pre-treatment levels and remained above placebo within 18 months of the last dose. These data indicate that continued treatment with Prolia is required to maintain the effect of the medicinal product. Re-initiation of Prolia resulted in gains in BMD similar to those when Prolia was first administered.</p><p><em>&nbsp;</em></p><p><em>Open-label extension study in the treatment of postmenopausal osteoporosis</em></p><p>A total of 4,550 women (2,343 Prolia &amp; 2,207 placebo) who missed no more than one dose of investigational product in the pivotal study described above and completed the month 36 study visit agreed to enrol in a 7-year, multinational, multicentre, open-label, single-arm extension study to evaluate the long-term safety and efficacy of Prolia. All women in the extension study were to receive Prolia 60&nbsp;mg every 6 months, as well as daily calcium (at least 1&nbsp;g) and vitamin D (at least 400&nbsp;IU). A total of 2,626 subjects (58% of the women included in the extension study i.e. 34% of the women included in the pivotal study) completed the extension study.</p><p>&nbsp;</p><p>In patients treated with Prolia for up to 10&nbsp;years, BMD increased from the pivotal study baseline by 21.7% at the lumbar spine, 9.2% at the total hip, 9.0% at the femoral neck, 13.0% at the trochanter and 2.8% at the distal 1/3 radius. The mean lumbar spine BMD T-score at the end of the study was &minus;1.3 in patients treated for 10 years.</p><p>&nbsp;</p><p>Fracture incidence was evaluated as a safety endpoint but efficacy in fracture prevention cannot be estimated due to high number of discontinuations and open-label design. The cumulative incidence of new vertebral and non‑vertebral fractures were approximately 6.8% and 13.1% respectively, in patients who remained on denosumab treatment for 10 years (n&nbsp;=&nbsp;1,278). Patients who did not complete the study for any reason had higher on-treatment fracture rates.</p><p>&nbsp;</p><p>Thirteen adjudicated cases of osteonecrosis of the jaw (ONJ) and two adjudicated cases of atypical fractures of the femur occurred during the extension study.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in men</u><u> </u><u>with osteoporosis </u></p><p><u>&nbsp;</u></p><p>Efficacy and safety of Prolia once every 6 months for 1 year were investigated in 242 men aged 31-84 years. Subjects with an eGFR &lt; 30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> were excluded from the study. All men received calcium (at least 1,000&nbsp;mg) and vitamin&nbsp;D (at least 800&nbsp;IU) supplementation daily.</p><p>&nbsp;</p><p>The primary efficacy variable was percent change in lumbar spine BMD, fracture efficacy was not evaluated. Prolia significantly increased BMD at all clinical sites measured, relative to placebo at 12&nbsp;months: 4.8% at lumbar spine, 2.0% at total hip, 2.2% at femoral neck, 2.3% at hip trochanter, and 0.9% at distal 1/3 radius (all p&nbsp;&lt;&nbsp;0.05). Prolia increased lumbar spine BMD from baseline in 94.7% of men at 1 year. Significant increases in BMD at lumbar spine, total hip, femoral neck and hip trochanter were observed by 6 months (p&nbsp;&lt;&nbsp;0.0001).</p><p>&nbsp;</p><p><u>Bone histology</u><u> </u><u>in postmenopausal women and men with osteoporosis</u></p><p><u>&nbsp;</u></p><p>Bone histology was evaluated in 62 postmenopausal women with osteoporosis or with low bone mass who were either na&iuml;ve to osteoporosis therapies or had transitioned from previous alendronate therapy following 1-3 years treatment with Prolia. Fifty nine women participated in the bone biopsy sub-study at month 24 (n&nbsp;=&nbsp;41) and/or month 84 (n&nbsp;=&nbsp;22) of the extension study in postmenopausal women with osteoporosis. Bone histology was also evaluated in 17 men with osteoporosis following 1 year treatment with Prolia. Bone biopsy results showed bone of normal architecture and quality with no evidence of mineralisation defects, woven bone or marrow fibrosis. Histomorphometry findings in the extension study in postmenopausal women with osteoporosis showed that the antiresorptive effects of Prolia, as measured by activation frequency and bone formation rates, were maintained over time.</p><p><em>&nbsp;</em></p><p><u>Clinical efficacy and safety in patients with bone loss associated with androgen deprivation</u></p><p><u>&nbsp;</u></p><p>Efficacy and safety of Prolia once every 6 months for 3 years were investigated in men with histologically confirmed non-metastatic prostate cancer receiving ADT (1,468 men aged 48-97 years) who were at increased risk of fracture (defined as &gt;&nbsp;70 years, or &lt;&nbsp;70 years with a BMD T‑score at the lumbar spine, total hip, or femoral neck &lt;&nbsp;‑1.0 or a history of an osteoporotic fracture). All men received calcium (at least 1,000&nbsp;mg) and vitamin&nbsp;D (at least 400&nbsp;IU) supplementation daily.</p><p>&nbsp;</p><p>Prolia significantly increased BMD at all clinical sites measured, relative to treatment with placebo at 3 years: 7.9% at the lumbar spine, 5.7% at the total hip, 4.9% at the femoral neck, 6.9% at the hip trochanter, 6.9% at the distal 1/3 radius and 4.7% at the total body (all p&nbsp;&lt;&nbsp;0.0001). In a prospectively planned exploratory analysis, significant increases in BMD were observed at the lumbar spine, total hip, femoral neck and the hip trochanter 1 month after the initial dose.</p><p>&nbsp;</p><p>Prolia demonstrated a significant relative risk reduction of new vertebral fractures: 85% (1.6% absolute risk reduction) at 1 year, 69% (2.2% absolute risk reduction) at 2 years and 62% (2.4% absolute risk reduction) at 3 years (all p&nbsp;&lt;&nbsp;0.01).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in patients with bone loss associated with adjuvant aromatase inhibitor therapy</u></p><p><u>&nbsp;</u></p><p>Efficacy and safety of Prolia once every 6 months for 2 years were investigated in women with non‑metastatic breast cancer (252 women aged 35-84 years) and baseline BMD T-scores between ‑1.0&nbsp;to&nbsp;‑2.5 at the lumbar spine, total hip or femoral neck. All women received calcium (at least 1,000&nbsp;mg) and vitamin&nbsp;D (at least 400&nbsp;IU) supplementation daily.</p><p>&nbsp;</p><p>The primary efficacy variable was percent change in lumbar spine BMD, fracture efficacy was not evaluated. Prolia significantly increased BMD at all clinical sites measured, relative to treatment with placebo at 2&nbsp;years: 7.6% at lumbar spine, 4.7% at total hip, 3.6% at femoral neck, 5.9% at hip trochanter, 6.1% at distal 1/3 radius and 4.2% at total body (all p&nbsp;&lt;&nbsp;0.0001).</p><p><u>&nbsp;</u></p><p><u>Treatment of bone loss associated with systemic glucocorticoid therapy</u></p><p>&nbsp;</p><p>Efficacy and safety of Prolia were investigated in 795&nbsp;patients (70% women and 30% men) aged 20 to 94 years treated with &ge;&nbsp;7.5&nbsp;mg daily oral prednisone (or equivalent).</p><p>&nbsp;</p><p>Two subpopulations were studied: glucocorticoid-continuing (&ge;&nbsp;7.5&nbsp;mg daily prednisone or its equivalent for &ge;&nbsp;3 months prior to study enrolment; n&nbsp;=&nbsp;505) and glucocorticoid-initiating (&ge;&nbsp;7.5&nbsp;mg daily prednisone or its equivalent for &lt;&nbsp;3 months prior to study enrolment; n&nbsp;=&nbsp;290). Patients were randomised (1:1) to receive either Prolia 60&nbsp;mg subcutaneously once every 6&nbsp;months or oral risedronate 5&nbsp;mg once daily (active control) for 2 years. Patients received calcium (at least 1,000&nbsp;mg) and vitamin D (at least 800&nbsp;IU) supplementation daily.</p><p>&nbsp;</p><p><em>Effect on Bone Mineral Density (BMD) </em></p><p>In the glucocorticoid-continuing subpopulation, Prolia demonstrated a greater increase in lumbar spine BMD compared to risedronate at 1 year (Prolia 3.6%, risedronate 2.0%; p &lt; 0.001) and 2 years (Prolia 4.5%, risedronate 2.2%; p &lt; 0.001). In the glucocorticoid-initiating subpopulation, Prolia demonstrated a greater increase in lumbar spine BMD compared to risedronate at 1 year (Prolia 3.1%, risedronate 0.8%; p &lt; 0.001) and 2 years (Prolia 4.6%, risedronate 1.5%; p &lt; 0.001).</p><p>&nbsp;</p><p>In addition, Prolia demonstrated a significantly greater mean percent increase in BMD from baseline compared to risedronate at the total hip, femoral neck, and hip trochanter.</p><p>&nbsp;</p><p>The study was not powered to show a difference in fractures. At 1 year, the subject incidence of new radiological vertebral fracture was 2.7% (denosumab) versus 3.2% (risedronate). The subject incidence of non-vertebral fracture was 4.3% (denosumab) versus 2.5% (risedronate). At 2 years, the corresponding numbers were 4.1% versus 5.8% for new radiological vertebral fractures and 5.3% versus 3.8% for non-vertebral fractures. Most of the fractures occurred in the GC-C subpopulation.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Prolia in all subsets of the paediatric population in the treatment of bone loss associated with sex hormone ablative therapy, and in subsets of the paediatric population below the age of 2 in the treatment of osteoporosis. See section 4.2 for information on paediatric use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Following subcutaneous administration of a 1.0&nbsp;mg/kg dose, which approximates the approved 60&nbsp;mg dose, exposure based on AUC was 78% as compared to intravenous administration at the same dose level. For a 60&nbsp;mg subcutaneous dose, maximum serum denosumab concentrations (C<sub>max</sub>) of 6&nbsp;mcg/mL (range 1-17&nbsp;mcg/mL) occurred in 10&nbsp;days (range 2‑28&nbsp;days).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Denosumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>After C<sub>max</sub>, serum levels declined with a half-life of 26 days (range 6-52 days) over a period of 3&nbsp;months (range 1.5-4.5 months). Fifty-three percent (53%) of patients had no measurable amounts of denosumab detected at 6 months post-dose.</p><p>&nbsp;</p><p>No accumulation or change in denosumab pharmacokinetics with time was observed upon subcutaneous multiple-dosing of 60&nbsp;mg once every 6 months. Denosumab pharmacokinetics were not affected by the formation of binding antibodies to denosumab and were similar in men and women. Age (28-87 years), race and disease state (low bone mass or osteoporosis; prostate or breast cancer) do not appear to significantly affect the pharmacokinetics of denosumab.</p><p>&nbsp;</p><p>A trend was observed between higher body weight and lower exposure based on AUC and C<sub>max</sub>. However, the trend is not considered clinically important, since pharmacodynamic effects based on bone turnover markers and BMD increases were consistent across a wide range of body weight.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p><u>&nbsp;</u></p><p>In dose ranging studies, denosumab exhibited non-linear, dose-dependent pharmacokinetics, with lower clearance at higher doses or concentrations, but approximately dose-proportional increases in exposures for doses of 60&nbsp;mg and greater.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>In a study of 55 patients with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics of denosumab.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>No specific study in patients with hepatic impairment was performed. In general, monoclonal antibodies are not eliminated via hepatic metabolic mechanisms. The pharmacokinetics of denosumab is not expected to be affected by hepatic impairment.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The pharmacokinetic profile in paediatric populations has not been assessed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single and repeated dose toxicity studies in cynomolgus monkeys, denosumab doses resulting in 100 to 150 times greater systemic exposure than the recommended human dose had no impact on cardiovascular physiology, male or female fertility, or produced specific target organ toxicity.</p><p>&nbsp;</p><p>Standard tests to investigate the genotoxicity potential of denosumab have not been evaluated, since such tests are not relevant for this molecule. However, due to its character it is unlikely that denosumab has any potential for genotoxicity.&nbsp;</p><p>&nbsp;</p><p>The carcinogenic potential of denosumab has not been evaluated in long-term animal studies.</p><p>&nbsp;</p><p>In preclinical studies conducted in knockout mice lacking RANK or RANKL, impairment of lymph node formation was observed in the foetus. An absence of lactation due to inhibition of mammary gland maturation (lobulo-alveolar gland development during pregnancy) was also observed in knockout mice lacking RANK or RANKL.</p><p>&nbsp;</p><p>In a study of cynomolgus monkeys dosed with denosumab during the period equivalent to the first trimester at AUC exposures up to 99-fold higher than the human dose (60&nbsp;mg every 6 months), there was&nbsp;no evidence of maternal or foetal harm. In this study, foetal lymph nodes were not examined.</p><p>&nbsp;</p><p>In another study of cynomolgus monkeys dosed with denosumab throughout pregnancy at AUC exposures 119-fold higher than the human dose (60&nbsp;mg every 6 months), there were&nbsp;increased stillbirths and postnatal mortality; abnormal bone growth resulting in reduced bone strength, reduced haematopoiesis, and tooth malalignment; absence of peripheral lymph nodes; and decreased neonatal growth. A no observed adverse effect level for reproductive effects was not established. Following a 6&nbsp;month period after birth, bone related changes showed recovery and there was no effect on tooth eruption. However, the effects on lymph nodes and tooth malalignment persisted, and minimal to moderate mineralisation in multiple tissues was seen in one animal (relation to treatment uncertain). There was no evidence of maternal harm prior to labour; adverse maternal effects occurred infrequently during labour. Maternal mammary gland development was normal.</p><p>&nbsp;</p><p>In preclinical bone quality studies in monkeys on long-term denosumab treatment, decreases in bone turnover were associated with improvement in bone strength and normal bone histology. Calcium levels were transiently decreased and parathyroid hormone levels transiently increased in ovariectomized monkeys treated with denosumab.</p><p>&nbsp;</p><p>In male mice genetically engineered to express huRANKL (knock-in mice), which were subjected to a transcortical fracture, denosumab delayed the removal of cartilage and remodelling of the fracture callus compared to control, but biomechanical strength was not adversely affected.</p><p>&nbsp;</p><p>Knockout mice (see section 4.6) lacking RANK or RANKL exhibited decreased body weight, reduced bone growth and lack of tooth eruption. In neonatal rats, inhibition of RANKL (target of denosumab therapy) with high doses of a construct of osteoprotegerin bound to Fc (OPG-Fc) was associated with inhibition of bone growth and tooth eruption. These changes were partially reversible in this model when dosing with RANKL inhibitors was discontinued. Adolescent primates dosed with denosumab at 27 and 150 times (10 and 50&nbsp;mg/kg dose) the clinical exposure had abnormal growth plates. Therefore, treatment with denosumab may impair bone growth in children with open growth plates and may inhibit eruption of dentition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each 1&nbsp;mL contains:</p><p>Acetic acid, glacial*: 1&nbsp;mg</p><p>Sodium hydroxide (for pH adjustment)*: titrate<sup>d</sup></p><p>Sorbitol (E420): 47&nbsp;mg</p><p>Polysorbate 20: 0.1&nbsp;mg</p><p>Water for injections: <sup>qs</sup></p><p>* Acetate buffer is formed by mixing acetic acid with sodium hydroxide</p><p><sup>qs</sup>quantum sufficit</p><p><sup>d </sup>Sodium content is approximately 0.013&nbsp;mmol or 0.3&nbsp;mg per dose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

Once removed from the refrigerator, Prolia may be stored at room temperature (up to 25°C) for up to 30 days in the original container. It must be used within this 30 days period.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Keep the container in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One&nbsp;mL solution in a single use pre-filled syringe made from type I glass with stainless steel 27 gauge needle, with a needle guard.</p><p>&nbsp;</p><p>Pack size of one pre-filled syringe, presented in blistered packaging (pre-filled syringe with a needle guard).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before administration, the solution should be inspected. Do not inject the solution if it contains particles, or is cloudy or discoloured.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To avoid discomfort at the site of injection, allow the pre-filled syringe to reach room temperature (up to 25&deg;C) before injecting and inject slowly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject the entire contents of the pre-filled syringe.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amgen Europe B.V.
Minervum 7061
NL-4817 ZK Breda
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>